Want to see DRMA full AI Analyst Report?
DRMA Stock Chart & Stats
$1.32
-$0.02(-1.52%)
At close: 4:00 PM EDT
$1.32
-$0.02(-1.52%)
Day’s Range― - ―
52-Week Range$0.95 - $6.22
Previous CloseN/A
Volume20.28K
Average Volume (3M)249.42K
Market Cap
$5.55M
Enterprise Value$0.78
Total Cash (Recent Filing)$4.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.39
Shares Outstanding4,022,143
10 Day Avg. Volume611,626
30 Day Avg. Volume249,418
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside203.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$15.00M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free structure avoids interest expense and reduces solvency pressure while Dermata funds development and commercialization. This gives the company greater flexibility than a similarly loss-making biotech carrying material debt obligations.
Commercialization TransitionLaunching Tome represents a durable shift from a pre-revenue clinical-stage model toward direct consumer sales. Establishing an initial product, customer base, and distribution channel could create a platform for future skincare launches and recurring revenue.
Fresh Operating FundingNew capital supports consumer research, launch activities, working capital, and the direct-to-consumer pivot. Insider participation may also indicate management commitment, while the funding provides resources to pursue commercialization before revenue is established.
Bears Say
No Revenue And Persistent LossesDermata has yet to demonstrate product-market traction or operating leverage, with losses continuing across every reported period. Until commercialization produces meaningful sales, the business remains dependent on external capital and vulnerable to setbacks in execution.
Sustained Cash BurnNegative operating and free cash flow show that ongoing research, corporate costs, and commercialization require substantial funding. Continued burn can shorten the company’s financial runway and force additional financing before the new consumer business becomes self-sustaining.
Thin And Declining EquityA shrinking equity base and modest total assets limit balance-sheet flexibility as losses continue. The new share and warrant issuance also increases potential dilution, making future capital needs more costly for existing shareholders if cash generation remains weak.
Dermata Therapeutics News
DRMA FAQ
What was Dermata Therapeutics’s price range in the past 12 months?
Dermata Therapeutics lowest stock price was $0.95 and its highest was $6.22 in the past 12 months.
What is Dermata Therapeutics’s market cap?
Dermata Therapeutics’s market cap is $5.55M.
When is Dermata Therapeutics’s upcoming earnings report date?
Dermata Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 88 days.
How were Dermata Therapeutics’s earnings last quarter?
Dermata Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.55 by -$0.19.
Is Dermata Therapeutics overvalued?
According to Wall Street analysts Dermata Therapeutics’s price is currently Undervalued.
Does Dermata Therapeutics pay dividends?
Dermata Therapeutics does not currently pay dividends.
What is Dermata Therapeutics’s EPS estimate?
Dermata Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Dermata Therapeutics have?
Dermata Therapeutics has 4,022,143 shares outstanding.
What happened to Dermata Therapeutics’s price movement after its last earnings report?
Dermata Therapeutics reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.55. Following the earnings report the stock price went up 27.778%.
Which hedge fund is a major shareholder of Dermata Therapeutics?
Currently, no hedge funds are holding shares in DRMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dermata Therapeutics
Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company in the dermatology sector focused on developing and commercializing new treatments for skin diseases and aesthetic dermatology conditions. The company’s pipeline has included DMT310 (a once-monthly topical product candidate for acne) and DMT410 (a topical product candidate investigated for multiple dermatologic conditions). As a clinical-stage company, Dermata is primarily engaged in research and development and does not have broad, established commercial product sales publicly available.
DRMA Stock 12 Month Forecast
Average Price Target
$4.00
▲(203.03% Upside)
Technical Analysis
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
25.41% Insiders
0.56% Mutual Funds
0.79% Other Institutional Investors
73.24% Public Companies and
Individual Investors